PRINCETON, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Covance (NYSE: CVD)
today achieved a successful settlement to its lawsuit against PETA, in which
PETA agreed to a ban on conducting any infiltration of Covance for five years.
In addition, PETA's operative, Lisa Leitten, accepted a three-year ban on
infiltrating any commercial animal research facility worldwide. PETA and
Leitten must also provide all video footage and written notes taken from
Covance. The settlement was confirmed by the Circuit Court of Fairfax County,
which entered an order requiring PETA and Leitten to comply with these
requirements.
"This resolution achieves our key goals of the lawsuit: to obtain a ban on
infiltration and to demonstrate that Covance will not tolerate such unlawful
acts by those who seek to block important biomedical research," said James
Lovett, Senior Vice President and General Counsel at Covance. "The strength
of our case enabled us to achieve these goals quickly via this settlement."
"Our business is devoted to helping develop new medicines for diseases
such as breast cancer, diabetes, leukemia, Alzheimer's, heart disease and
HIV/AIDS," said Lovett. "The research we perform is essential to ensuring
that these medicines are safe and effective before they are made available to
patients."
A copy of the settlement can be found at
http://www.covance.com/animalwelfare/media-resources.php.
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1 billion, global operations in 17 countries, and more
than 7,000 employees worldwide. Information on Covance's products and
services, recent press releases, and SEC filings can be obtained through its
website at http://www.covance.com.
SOURCE Covance
 back to top
Related links:
http://www.covance.com
http://www.covance.com/animalwelfare/media-resources.php
CONTACT:
Media, +1-609-419-2060; Investors,
+1-609-452-4807
|
